Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219-229.

Boyraz B, Tajiri R, Alwaqfi RR, Paula AD, Ye Q, G Nielsen P, et al. Vulvar angiomyofibroblastoma is molecularly defined by recurrent MTG1-CYP2E1 fusions. Histopathology. 2022;81(6):841-846.

Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, et al. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022;15(1):3-10.

Liu C, Zhou N, Levitan D, Guzman JC, Fehniger J. Cutaneous metastasis of PD-L1 positive cervical carcinoma. Gynecol Oncol Rep. 2022;41:101003.

McLean-Holden AC, Rooper LM, Lubin DJ, Magliocca KR, Manucha V, Sadow PM, et al. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. Head Neck Pathol. 2022;16(3):657-669.

Kato T, Asakura T, Edwards CE, Dang H, Mikami Y, Okuda K, et al. Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. Am J Respir Crit Care Med. 2022;206(11):1336-1352.

Tow CY, Castrodad-Rodríguez CA, Panarelli N, Massoumi H. Finding Nivo: A Case Report of 2 Forms of Nivolumab-Induced Liver Injury in an Allograft Liver in the Immediate Post-Transplant Period. Transplant Proc. 2022;54(10):2794-2796.

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022;376(6596):eabe1505.

Magro CM, Mo JH, Kerns MJ. Leukocytoclastic vasculitis in association with linear epidermal basement membrane zone immunoglobulin deposition: Linear vasculitis. Clin Dermatol. 2022;40(6):639-650.

Fangusaro JR, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman NI, et al. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol. 2022;24(8):1404.